
Search
Filter Results
Displaying 581–590 of 688 for “retinitis clinical trial”
-
Jul 22, 2022
Apellis’ Treatment for Advanced Dry AMD to Receive Priority Review from FDA
There are currently no FDA-approved therapies for geographic atrophy (GA), the advanced form of dry AMD.
-
Jul 21, 2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair. Ophthalmology luminaries Jean Bennett, MD, PhD, Catherine Bowes Rickman, PhD, and José-Alain Sahel, MD, to join the board.
-
VISIONS 2022 Session Recordings
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Jun 20, 2022
Biologist and Father Dedicated to Daughter’s Cure
After Allison’s diagnosis with Usher syndrome type 3, her dad, Jeff Libby, wanted to do everything he could to find her a cure. As a biologist, Jeff started searching for organizations researching blinding diseases like Allison’s, and he found the Foundation Fighting Blindness.
-
May 12, 2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
May 12, 2022
Foundation Fighting Blindness to Host VISIONS 2022 Conference
The national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
-
May 9, 2022
Cleanlogic Co-Founder’s Inspiration Comes From His Mom
In honor of Mother’s Day, we’re sharing a special Beacon Story featuring Isaac Shapiro, co-founder of Cleanlogic. Isaac’s mother, Bea, lost her vision at only seven years old but went on to become an entrepreneur and help others in the blind and visually impaired community through adaptive technology.
-
XLRP-Patient Focused Drug Development
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
Mar 3, 2022
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
Industry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Feb 1, 2022
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
This new treatment can reduce the frequency of injections into the eye